WuXi AppTec’s wholly-owned subsidiary WuXi Advanced Therapies (WuXi ATU) has announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to improve scalability and accessibility of cell and gene therapies.
The new technology, which is developed by Oxgene, offers a scalable process to manufacture gene therapies.
It also helps to accelerate the production of therapeutic DNA required for the treatment of patients in need.
TESSA will expedite the manufacturing of adeno-associated virus (AAV) and reduce the costs to produce cell and gene therapies.
The company stated that the new technology will allow its global customers to develop and deliver accessible therapies for patients as quickly as possible.
WuXi ATU chief scientific officer Dr Ryan Cawood said: “The TESSA system is a game-changer for the manufacture of AAV and the advancement of cell and gene therapies to benefit patients.
“By improving scalability, reducing process complexity and lowering the costs of gene therapy manufacture, TESSA will better enable our global partners to develop and deliver life-saving gene therapies faster to more patients in need.”
Furthermore, new data published in Nature Communications supports the benefits of the new TESSA technology.
It noted that TESSA vectors manufactured ten times more AAV compared to plasmid-based manufacture.
This produces enough material to treat ten times the number of patients.
Last November, the company opened its advanced therapies testing facility in Philadelphia, Pennsylvania, US.
With 140,000ft² laboratories, the facility has enhanced the company’s contract testing, development and manufacturing organisation business model by tripling its previous testing capacity.